RESOLUTION OF THE EUROPEAN PARLIAMENT  
of 10 May 2012  
with observations forming an integral part of its Decision on discharge in respect of the 
implementation of the budget of the European Medicines Agency for the financial year 2010  
THE EUROPEAN PARLIAMENT,  
— having regard to the final annual accounts of the European Medicines Agency for the financial year 
2010,  
— having regard to the Court of Auditors’ report on the annual accounts of the European Medicines 
Agency for the financial year 2010, together with the Agency’s replies (  1 ), 
— having regard to the Council’s recommendation of 21 February 2012 (06083/2012 – C7-0051/2012),  
— having regard to Article 319 of the Treaty on the Functioning of the European Union,  
— having regard to Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial 
Regulation applicable to the general budget of the European Communities (  2 ), and in particular 
Article 185 thereof,  
— having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council (  3 ) 
establishing a European Medicines Agency, and in particular Article 68 thereof,  
— having regard to Commission Regulation (EC, Euratom) No 2343/2002 of 19 November 2002 on the 
framework Financial Regulation for the bodies referred to in Article 185 of Council Regulation (EC, 
Euratom) No 1605/2002 on the Financial Regulation applicable to the general budget of the European 
Communities (  4 ), and in particular Article 94 thereof,  
— having regard to Rule 77 of, and Annex VI to, its Rules of Procedure,  
— having regard to the report of the Committee on Budgetary Control and the opinion of the Committee 
on the Environment, Public Health and Food Safety (A7-0107/2012),  
A. whereas the Court of Auditors, in its report on the annual accounts of the European Medicines Agency 
for the financial year 2009, qualified its opinion on the legality and regularity of the underlying trans ­
actions,  
B. whereas in its Decision of 10 May 2011, Parliament decided to postpone its decision on granting the 
Executive Director of the Agency discharge in respect of the implementation of its budget for 2009 (  5 ) 
but then granted it in its Decision of 25 October 2011 (  6 ), 
C. whereas on 25 October 2011 Parliament granted the Executive Director of the Agency discharge for 
implementation of the Agency’s budget for the financial year 2009, and in its resolution accompanying 
the discharge decision, inter alia:  
— emphasises that the discharge authority should continue to carefully monitor during the upcoming 
discharge procedures the level of implementation of the measures undertaken to address the 
Agency’s serious weaknesses disclosed by the reports from both the Court of Auditors and the 
Internal Audit Service (IAS),EN L 286/378 Official Journal of the European Union 17.10.2012  
( 1 ) OJ C 366, 15.12.2011, p. 27.  
( 2 ) OJ L 248, 16.9.2002, p. 1.  
( 3 ) OJ L 136, 30.4.2004, p. 1.  
( 4 ) OJ L 357, 31.12.2002, p. 72.  
( 5 ) OJ L 250, 27.9.2011, p. 173.  
( 6 ) OJ L 313, 26.11.2011, p. 27.
— called on the Agency to inform the discharge authority of the action taken on issues relating to 
effective compliance with its Code of Conduct as regards the management of conflicts of interest,  
— insisted, but also warned the Agency, that all the action mentioned in the respective audit reports, 
including the one for the year 2010, should be fully implemented before the start of the next 
discharge procedure,  
D. whereas the Court of Auditors has stated that it has obtained reasonable assurances that the annual 
accounts for the financial year 2010 are reliable and that the underlying transactions are legal and 
regular,  
E. whereas the budget of the Agency for 2010 was EUR 208 400 000, which represents an increase of 
7,20 % over the financial year 2009;  
F. whereas the initial contribution of the Union to the budget of the Agency for 2010 was 
EUR 28 279 600 compared with EUR 36 390 000 in 2009 (  1 ), and whereas the overall contribution 
of the Union to the budget of the Agency for 2010 was EUR 36 600 100,  
Follow-up of 2009 discharge  
1. Expects the Agency to inform the discharge authority of the results of the action taken with regard to 
the following issues:  
— the process of adoption by the Management Board of the action plan with specific measures and a 
timetable for implementation to remedy the shortcomings identified in the procurement 
procedures;  
— the thorough verification of the effective use of the existing procedures for the identification and 
management of conflicts of interest for its staff and experts;  
calls on the Court of Auditors to give reasonable assurances that the Agency has effectively addressed 
its shortcomings relating to procurement procedures, and on the IAS to give assurances the discharge 
authority on the effective use of existing procedures for the management of conflicts of interest for the 
Agency’s staff and experts;  
2. Calls on the Agency and on the IAS to immediately verify whether all the action specified in the audit 
reports, including that for 2010, were fully implemented and to inform the discharge authority 
accordingly;  
3. Notes from the Agency that on 15 December 2011 the Management Board endorsed a proposal for 
the Agency to present at the June 2012 meeting of the Management Board the detailed implementing 
measures related to the:  
— establishment of the new structure and scope of the Advisory Committee on Procurement and 
Contract,  
— implementation of a multiannual procurement plan,  
— establishment of the responsibilities for the above;  
insists that the Management Board sends the Action Plan to the discharge authority at the latest by 
30 June 2012;EN 17.10.2012 Official Journal of the European Union L 286/379  
( 1 ) OJ L 64, 12.3.2010, p. 445.
Budget and financial management  
4. Recalls that the initial Union contribution to the Agency for 2010 amounted to EUR 26 335 100; 
notes however that EUR 10 265 000 coming from the recovery of surplus, was added to that amount 
which, as a result, makes a total Union contribution of EUR 36 600 100 for 2010;  
5. Stresses that the general budget of the European Union for the financial year 2010, as definitively 
adopted, presents two different figures as the initial contribution of the Union to the budget of the 
Agency, i.e. EUR 28 279 600 and EUR 26 335 100; urges, therefore, the Commission to inform the 
discharge authority of the exact subsidy allocated to the Agency;  
6. Acknowledges that the Agency’s budget is financed both from the Union budget and from fees paid by 
the pharmaceutical industry when applying for, obtaining or maintaining Union marketing authori ­
sations; finds from the Annual Activity Report that in 2010, 73 % of the revenue of the Agency is 
estimated to have derived from the fee revenue and that, in parallel with the increase in the fee-based 
revenue, the relative percentage income from the Union contribution fell from 23 % in 2006 to 14 % 
in 2010;  
7. Finds from the Annual Activity Report that 17 exceptions were entered in the register of exceptions in 
2010;  
8. Notes weaknesses in the Agency’s system for validating creditor claims in respect of IT contractors; 
takes note of the Agency’s statement that the weaknesses noted by the Court of Auditors related to a 
human error and were corrected, that it has strengthened its  ex-ante  operational and financial control 
of invoices and that no further weaknesses have been detected; invites the Court of Auditors to verify 
and inform Parliament in this respect;  
Carryover appropriations and cancellations  
9. Acknowledges from the Agency’s Report on budgetary and financial management that automatic 
carryovers to the 2011 financial year totalled EUR 41 655 049,44, or 20,90 % of the appropriation 
committed, and that one non-automatic carryover to the 2011 financial year was requested totalling 
EUR 3 500 000, or 1,68 % of the final appropriation;  
10. Is concerned that the Court of Auditors has once more reported a high carryover of EUR 17 600 000 
in Title II (Administrative expenditure); stresses that this situation indicates delays in the implemen ­
tation of activities financed from Title II of the Agency’s budget and that the Agency is not complying 
with the budgetary principle of annuality;  
11. Notes with concern the additional comment from the Court of Auditors that only 36 % of the 
appropriations carried forward to 2011 correspond to expenditure accrued from 2010, while the 
remaining 64 % of amounts carried over did not relate to the 2010 financial year;  
12. Points out that the Court of Auditors had already reported a high level of carryovers in previous 
financial years; notes, in particular, that in the 2009 budget the Court of Auditors reported a carryover 
of EUR 19 500 000 (38 % of the Agency’s commitments) and in 2008 it was EUR 36 000 000 
(19,7 % of the 2008 budget);  
13. Establishes from the Agency’s Report on budgetary and financial management that in 2010, appropri ­
ations totalling EUR 9 074 296,49 were cancelled compared with EUR 7 693 276,58 in 2009; notes 
the Agency’s reply that the level of cancelled expenditure appropriations is a result of stringent 
monitoring of actual revenue and adjustments to expenditure; urges the Agency to take immediate 
action to reduce the level of cancelled appropriations and to adopt an Action Plan with concrete 
measures — including aimed at a stricter estimation of the fee income and the period to be received 
— and deadlines to address this persistent problem by 30 June 2012;EN L 286/380 Official Journal of the European Union 17.10.2012
Procurement Procedures and Transfers  
14. Ascertains from the Annual Activity Report that, in addition to the 165 specific contracts concluded 
under framework contracts, 70 new procurement contracts exceeding EUR 25 000 in value were 
concluded by the Agency during 2010;  
15. Notes from the Agency’s Report on budgetary and financial management that, during 2010, 13 
transfers of a total amount of EUR 13 714 500 (15,29 % of the final appropriations) were 
approved; further notes that the Agency already adopted 10 transfers of a total amount of 
EUR 9 609 000 in 2009; calls on the Agency to adopt an Action Plan with concrete measures and 
deadlines to remedy this persistent problem;  
System of remuneration for services  
16. Urges the Agency to introduce a system of remuneration for services provided by national Member 
State authorities based on the Member States’ real costs; also calls on the Agency to promptly inform 
the discharge authority when this system is put in place; notes in this regards that a new payment 
system was already presented to the Management Board at their meeting of 10 December 2009 but it, 
in the end, rejected the proposal;  
17. Supports all efforts at the executive and administrative levels of the Agency to reform the payment 
system for services provided by Member States’ authorities which should clearly be based on the real 
costs; urges the Management Board to move forward on this issue;  
18. Notes that by refusing a new payment system, the Management Board accepts and takes direct 
responsibility for very important risks, such as non-compliance with legislative requirements, the 
potential financial impact of the current remuneration system, and reputation; is therefore not 
ready to accept this questionable attitude from the Management Board and calls on the Agency to 
adopt an Action Plan on this matter and to inform the discharge authority by 30 June 2012;  
Human resources management  
19. Urges the Agency to strengthen its recruitment processes and ensure that its documentation is 
correctly managed; calls in particular on the Agency to improve the documentation of the recruitment 
files for contract agents and on the Appointing Authority to adopt the reserve lists proposed by the 
selection committees;  
20. Acknowledges also from the Court of Auditors that the Agency did not distinguish sufficiently 
between employment-agency staff and contract staff recruitment; calls therefore on the Agency to 
use employment-agency staff to cover short-term needs only and grant transparent access for contract 
staff positions;  
Management of conflict of interest  
21. Urges the Agency to provide central coordination for the development of a common experts’ 
assessment methodology applicable to all national competent authorities and for its monitoring; 
notes that, after the Memorandum of Understanding (MoU) signed between the Agency and each 
national competent authority on the monitoring of the scientific level of the experts became effective 
on 4 July 2011, the Agency still has responsibility for developing and coordinating a common experts’ 
assessment and experts’ methodology;  
22. Emphasises that the Agency needs to finalise the signing of MoUs on the independence of scientific 
evaluation, to amend internal procedures correspondingly, and to update the experts’ database; takes 
note of the Agency’s reply that MoUs on the independence of scientific evaluation have been signed as 
of October 2011 and that the experts’ database was updated to allow for the direct uploading of the 
electronic declarations of interest into the database; calls on the Agency to inform the discharge 
authority of the status of implementation of these measures by 30 June 2012; also invites the IAS 
to inform the discharge authority when these very important recommendations are effectively imple ­
mented by the Agency;EN 17.10.2012 Official Journal of the European Union L 286/381
23. Calls on the Agency to inform the discharge authority of the way in which it ensures that procedures 
for the involvement of experts are fully applied until the MoUs on the independence of scientific 
evaluation have been signed by all national competent authorities;  
24. Calls on the Agency to report on its involvement in the organisation of conferences by private 
organisations such as the Organisation for Professionals in Regulatory Affairs;  
25. Takes note from the Agency of the adoption on 1 February 2012 of the ‘Decision on rules relating to 
Articles 11a and 13 of the Staff Regulations concerning the handling of declared interests of 
employees of the European Medicines Agency’ by the Management Board and of the ‘Decision on 
rules concerning the handling of declared interests of national experts on secondment, visiting experts, 
trainees and interims of the European Medicines Agency’ by the Executive Director; calls on the 
Agency to inform the discharge authority of the concrete measures undertaken to implement these 
decisions by 30 June 2012 in order to enable Parliament to assess the procedures in place for handling 
potential conflicts of interest for all categories listed in the two decisions, plus the members of the 
Management Board;  
26. Notes with concern that in the financial circuits there are also potential conflicts of interests in 
processing payments due to insufficient segregation of duties; urges the Agency therefore to duly 
take into account this very significant risk and take immediate action to address this deficiency;  
27. Notes that the former Executive Director of the Agency wrote to the Agency on 28 December 2010 
outlining the activities which he was intending to take up at the end of his term of office; considers 
the first decision of 11 January 2011, taken by the Chairman of the Agency Management Board, to 
authorise the new activities of the former Executive Director of the Agency to be a breach of Union 
rules relating to conflicts of interest, in particular with regard to Title II, Article 16, of the Staff 
Regulations of the Officials of the European Union; recalls that according to Title II, Article 11, and 
title IV, Article 91, of the Conditions of Employment of Other Servants of the European Union, this 
provision applies by analogy to temporary agents and to contract employees; considers the fact that 
the Management Board adopted limitations on the future activities of the former Executive Director on 
17 March 2011 — only after strong public protest — to be clear proof that the Agency did initially 
not apply the Staff Regulations properly, which in turn raises serious questions about their application 
of the rules in general; asks the Executive Director to present a detailed report on the implementation 
of Article 16 of the Staff Regulations within the Agency;  
28. Is seriously concerned by the failure of the Agency and its Management Board to effectively address 
the matter of conflict of interests; takes note that in April 2012 the Agency adopted a revised policy 
on the handling of conflicts of interests of Scientific Committee members and experts, as well as a 
breach of trust procedure for Committee members and experts; insists that implementation and 
concrete results are the only elements to prove the efficiency of the new policy and procedure; 
believes that the Agency should verify, during 2012, all declarations of interest of experts and 
Scientific Committee members; therefore, calls on the Agency to provide data — figures and names 
included — following the enforcement of this procedure; calls also on the Agency to have verified at 
least 75 % of the experts’ declarations of interest and at least 75 % of the Scientific Committee 
members’ declarations of interest and to provide the discharge authority with the verification results 
and with an Action Plan with a calendar concerning the rest of the verification process for declarations 
of interest by the end of August 2012;  
29. Recalls that, following the employment of the Agency’s former Executive Director by a consultancy 
that advises, among others, pharmaceutical companies almost immediately after he left the Agency, the 
discharge authority raised concerns over the actual independence of the Agency and the way in which 
its Management Board implemented Article 16 of the Staff Regulations; is furthermore concerned by 
the allegations that the Agency’s former Executive Director created his own consultancy firm while still 
in office; calls on the Agency to provide the discharge authority with further information on this 
matter by 30 June 2012;  
30. Urges the Court of Auditors to finalise and present its current audit of conflict of interest in the 
Agency;EN L 286/382 Official Journal of the European Union 17.10.2012
31. Regrets the fact that many of the experts failed to publish their declarations of interests, and that the 
comparison of declarations of interests published by the relevant national agencies and by the Agency 
shows significant differences in some cases; deplores, furthermore, the fact that at least one member of 
the Management Board of the Agency, also substitute member of the Committee for Medicinal 
Products for Human Use, failed to declare his recent management responsibilities in a pharmaceutical 
firm;  
32. Welcomes the Agency’s initiative to publish the declarations of interests of its staff occupying 
management positions and of the experts involved in the evaluation of medicinal products on its 
website; notes with interest that the list of experts also indicates their risk level in terms of conflict of 
interest; believes that at least the previous working places – professional background – should also be 
published along with the declarations of interest to allow verification of the declarations of interest and 
identify possible conflicts; therefore invites the Agency to provide Parliament with information on the 
status of implementation of these measures by 30 June 2012;  
33. Urges the Agency to carry out checks on the declarations of interests submitted to it, and a detailed 
check on a random basis, notably by implementing a system under which declarations are cross- 
checked against information held by industry and by the relevant national agencies;  
34. Is nevertheless concerned by the Agency’s approach vis-à-vis the scrutiny of declarations of interest, 
which is primarily based on trust rather than on verification; is notably concerned by the fact that the 
comparison of the experts’ declaration of interest published by the relevant national agencies and by 
the Agency reveals significant discrepancies in some cases; therefore calls on the Agency to establish a 
genuine mechanism enabling proper scrutiny of the declarations of interest received by the Agency 
and to inform the discharge authority on this matter by 30 June 2012;  
35. Urges the Agency to apply its conflict of interest policy to its Management Board;  
36. Notes that the Agency has been audited by the Court of Auditors in the framework of the Special 
Report on conflicts of interest management in the Union agencies; acknowledges from the Court of 
Auditors that the above-mentioned Special Report will be published by the end of June 2012; is of the 
opinion that, given the extent of criticisms questioning conflict of interest issues in the Agency, the 
decision on discharge should be postponed until the publication of the Special Report to take into 
account the findings of the Court of Auditors in this respect;  
37. Considers that the effective management of conflict of interest is crucial to maintain public trust in the 
work of the Agency;  
38. Acknowledges the Agency’s willingness to publish the Declarations of Interests of experts involved in 
the evaluation of medicinal products; but deplores the fact that many of the experts have yet to 
publish their Declarations of Interests;  
39. Takes note of the fact that the Management Board adopted limitations on the subsequent professional 
activities of the former Executive Director on 17 March 2011 after public protest supported by 
Parliament regarding its decision in January 2011 to authorise his new activities fully; recalls in this 
context that a delegation of the Committee on the Environment, Public Health and Food Safety visited 
the Agency in June 2011 to follow up this case and to receive further information on the improved 
procedures; recalls, furthermore, that the Committee held an exchange of views with the Executive 
Director — designate in July 2011 where the issue was addressed again in order to avoid future 
recurrences;  
Performance  
40. Considers the assessment of the adequacy and effectiveness of the systems in place to support the 
provision of scientific advice for human medicines in the Agency as an important tool to measure the 
Agency’s performance;EN 17.10.2012 Official Journal of the European Union L 286/383
41. Takes note of the increased number of products and services (opinions, reports, scientific advice, 
inspections) compared with 2009; is also satisfied with the implementation of Regulation (EC) 
No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan 
medicinal products (  1 ) and encourages the Agency to continue its action to provide incentives for 
research, development and placing on the market of designated orphan medicinal products;  
Internal audit  
42. Acknowledges from the Agency that 11 ‘very important’ recommendations from the IAS still need to 
be implemented; notes that one of them has been reported as implemented by the Agency and is now 
under the IAS review;  
43. Is concerned that seven of these ‘very important’ recommendations have been delayed by up to more 
than 12 months; notes that these recommendations concern:  
— the compliance with Article 110 of the Staff Regulations;  
— the recruitment process;  
— the use of databases;  
— the definition of rules on filing for products;  
— the guidelines on the management of potential conflicts of interest of staff;  
— the procedures on involvement of experts;  
— the segregation of duties in the financial circuits;  
urges the Agency therefore to promptly address these deficiencies identified by the IAS and to inform 
the discharge authority of the measures taken;  
44. Is further concerned that the Agency rejected two ‘very important’ recommendations relating to:  
— the fees paid to national agencies;  
— the reduction in the number of consultants working in-house;  
urges the Agency to explain immediately to the discharge authority the rejection of these two recom ­
mendations;  
45. Notes that if the IAS in its follow-up report of September 2010 continues to find ‘inadequate 
assessment of the independence of the experts’, the Executive Director should publish a list of all 
the authorised medicinal products concerned and report how the Agency intends to rectify these 
procedures;  
46. Draws attention to its recommendations from previous discharge reports, as set out in the Annex to 
this resolution;  
47. Refers, in respect of the other observations accompanying its Decision on discharge, which are of a 
horizontal nature, to its resolution of 10 May 2012 (  2 ) on the performance, financial management and 
control of the agencies.EN L 286/384 Official Journal of the European Union 17.10.2012  
( 1 ) OJ L 18, 22.1.2000, p. 1.  
( 2 ) Texts adopted, P7_TA(2012)0164. (see page 388 of this Official Journal).
ANNEX  
EUROPEAN PARLIAMENT RECOMMENDATIONS OVER PAST YEARS  
European Medicines Agency  2006  2007  2008  2009  
Performance  n.a.  — The principle of sound financial 
management was not 
rigorously fulfilled: the 
Agency’s cash forecast had not 
been prepared properly 
— The Agency carries out its 
operations in two locations, 
exposing it to additional costs 
(direct posts: EUR 450 000)  — Good results in having put in place 
sophisticated activity-based budgeting and user- 
satisfaction monitoring 
— Calls on the Agency to reassess its brokerage 
policy in light of the financial risks incurred 
throughout the year 
— The Agency carries out its operations in two 
locations, exposing it to additional costs  — Unacceptable that the Agency does not apply 
the relevant rules for management of conflicts of 
interest effectively 
— 12 very important & 1 critical recommendations 
from several earlier IAS Annual Audit Reports 
were still not implemented in 2009 
Unacceptable that the Agency is not complying 
with its Code of Conduct, urges the Agency to 
document & assess its controls & file the 
relevant allocation decisions which must be 
made available on its website 
— Urges the Agency to inform the discharge 
authority of the steps it has taken to ensure the 
independence of its experts since its inception 
— Asks the Agency to complete & regularly update 
the European Experts Database as required by 
Regulation (EC) No 726/2004  
Carry-over of 
appropriations  The budgetary principle of 
annuality was not strictly observed: 
the utilisation rate for commitment 
appropriations was less than 60 %. 
more than 40 % of the 
commitments were carried over to 
the financial year 2007  The agency had difficulties in the 
programming, the budgeting of its 
activities, and their 
implementation: EUR 32 000 000 
euro were carried over and 
EUR 4 000 000 were cancelled: 
Calls on the agency to fulfil the 
principle of annuality  Calls on the Agency to fulfil the annuality 
principle: the budget appropriations carried over 
and cancelled have amounted respectively to 
EUR 36 000 000 (19,7 % of the budget) and 
EUR 9 700 000 (5,3 % of the budget)  Court of Auditors reports a carryover of 
EUR 19 500 000 (38 % of Agency’s commitments), 
EUR 14 800 000 of this was for activities not yet 
implemented at year end, indicates delays in the 
implementation of activities financed form Title II. 
Agency is not in accordance with budgetary 
principle of annuality  
Procurement procedures  n.a.  — Transparency issues at the level 
of selection criteria and at the 
level of the evaluation methods 
for the price criteria and joint 
procurement procedure 
— Recalls on improving 
procurement management  Calls on the Agency to improve the quality of its 
procurement procedures so as to put an end to the 
shortcomings: i.e. as regards the application of 
evaluation methods for the price criteria and as 
regards the essential need for justifications for the 
choice procedure  — Concerned that the Court of Auditors findings 
of errors in the procurement procedures 
corresponding to a significant amount of the 
Agency’s total budget for the financial year of 
2009. Shortcomings in evaluation criteria such 
as price and choice of procedures 
— Urges the Agency to improve the quality of its 
procurement procedures in order to put an end 
to the shortcomings identified by the Court of 
AuditorsEN 17.10.2012 Official Journal of the European Union L 286/385
European Medicines Agency  2006  2007  2008  2009  
— Calls on the Agency to set up a multiannual 
procurement plan 
— Calls on the Agency to ensure the results of 
procurement procedures are verified before 
contracts are awarded  
Revenue from fees  The Agency has not been able to 
make a comprehensive analysis of 
the costs incurred by Member 
States’ rapporteurs in order to 
obtain an objective and 
documented basis on which to 
adapt its payments to them, and 
consequently the fee charged to its 
customers: This situation was in 
breach of the Fee Regulation  Transparency issues on the amount 
repaid to the Member States’ 
rapporteurs  Calls on the Commission to evaluate the Agency’s 
endemic high level of cash holdings 
(EUR 41 887 000)  Calls on the Agency to ensure better coordination 
between its financial & scientific services in order to 
remedy the unacceptable long day of recovery 
orders  
Internal Audit  n.a.  n.a  Calls on the Agency to fulfil a ‘critical 
recommendation’ made the Commission’s Internal 
Audit Service related to the area of experts’ 
conflicts of interests, and other eight ‘very 
important’ recommendations in the areas of 
documentation of conflicts of interest for the 
Agency’s staff, databases used to support the 
administrative procedures for evaluation and 
development of guidelines for filing and full 
implementation of such guidelines  Unacceptable that the Executive Director’s statement 
of assurance does not mention any reservations 
which is inconsistent with the undertaking given in 
its Code of Conduct adopted by the Agency in the 
light of the statements of assurance from the IAS & 
the Court of Auditors 
Asks the Agency to forward the IAS reports since 
2007 to the discharge authority by 30 June 2011 
Urges the Agency to rapidly implement the IAS 
recommendations, provide the discharge authority 
with an overview of measures taken & implementedEN L 286/386 Official Journal of the European Union 17.10.2012